A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

Inclusion Criteria: * Normal healthy adult subjects between 20-50 years of age. * Body weight within 80-120% of ideal body weight. * Male Ideal body weight = (height - 80) x 0.7 * Female Ideal body weight = (height - 70) x 0.6 * Acceptable medical history and physical examination including: * normal ECG results within six months prior to dosing. * no particular clinical significance in general disease history within two months prior to dosing. * Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to dosing, which includes AST (SGOT), ALT (SGPT), r-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol, triglyceride (TG), PT(INR) and OGSP. * Acceptable hematology within two months prior to dosing, which includes hemoglobin, hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and platelets. * Acceptable urinalysis within two months prior to dosing, which includes pH, blood, glucose and protein. * Signed the written informed consent to participate in this study Exclusion Criteria: * History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years. * A clinically significant disorder involving the allergy, cardiovascular, respiratory, renal, gastrointesti…